Biotech Premarket Movers: Sucampo, Intellia, Cytokinetics

Shares of Sucampo Pharmaceuticals (SCMP) rose 6.7% to $12 in premarket trading Wednesday after the Rockville, Md.-based company announced better-than-expected results. Sucampo reported fourth-quarter adjusted earnings per diluted share of 68 cents on revenue of $73 million. Analysts had estimated adjusted earnings per share of 43 cents on revenue of $65.98 million, according to Bloomberg.

Sucampo reiterated full-year 2017 guidance. The company has forecast revenue of $220 million to $230 million, adjusted net income of $80 million to $90 million, adjusted diluted EPS of $1.35 to $1.50 and adjusted Ebitda of $145 million to $155 million.

Also on Wednesday, Sucampo named Peter Pfreundschuh its new chief financial officer effective March 20. Pfreundschuh succeeds Andrew Smith, who is leaving the company to move back to Europe with his family to pursue professional opportunities there.

In addition, Sucampo said Jones "Woody" Bryan, Ph.D. will become the new senior vice president of business development and licensing effective March 20.

Meanwhile, Intellia Therapeutics (NTLA) shares were up 5.5% to $13.75 after the Cambridge, Mass.-based company announced updated data that show "increased levels of genome editing efficiency in vivo and durability results with its CRISPR/Cas9 technology, following a single administration."

Other biotech stock movers include Cytokinetics (CYTK) , whose shares were up 4.4% to $12. Cytokinetics is a South San Francisco, Calif.-based muscle therapy company.

More from Health

Sprout CEO: Don't Call Her Drug the Female Viagra

Sprout CEO: Don't Call Her Drug the Female Viagra

What's the Difference Between CBD vs. THC?

What's the Difference Between CBD vs. THC?

How to Invest in Cannabis - In Its Many Forms

How to Invest in Cannabis - In Its Many Forms

Eli Lilly, AstraZeneca Shares Fall After Halting Alzheimer's Drug Test

Eli Lilly, AstraZeneca Shares Fall After Halting Alzheimer's Drug Test

There's Nothing Funny About Guardianship

There's Nothing Funny About Guardianship